Treatment of Rheumatoid Arthritis Flare
Immediate Flare Management
- The American College of Rheumatology recommends administering short-term systemic glucocorticoids at ≤10 mg/day prednisone equivalent for less than 3 months duration to bridge until DMARD optimization takes effect 1, 3
- For predominantly single-joint involvement, the American College of Rheumatology suggests using intra-articular glucocorticoid injection for targeted relief 2
- The risk-benefit ratio favors glucocorticoids only when dose is low and duration is short; avoid use beyond 1-2 years due to risks of cataracts, osteoporosis, fractures, and cardiovascular disease 1, 4
Disease Activity Assessment
- Measure disease activity using validated indices: SDAI >11 or CDAI >10 indicates moderate-to-high activity requiring aggressive escalation 2, 4
- Check inflammatory markers (CRP, ESR) and autoantibodies (rheumatoid factor, anti-CCP) to guide therapy selection 2
DMARD Optimization Strategy
- Optimize methotrexate to 20-25 mg/week (or maximum tolerated dose) before declaring treatment failure 2, 5
- Add sulfasalazine and hydroxychloroquine to create triple-DMARD therapy if methotrexate optimization fails to achieve low disease activity 2, 4, 5
- Add biologic DMARD or targeted synthetic DMARD rather than continuing to adjust conventional DMARDs 1, 3, 5
Biologic Switching Strategy for Persistent Flares
- Switch to a different mechanism of action rather than trying another TNF inhibitor 2, 5
- Options include: Tocilizumab (IL-6 receptor antagonist), Abatacept (T-cell costimulation modulator), and Rituximab (anti-CD20) 2, 4, 5, 6
Critical Pitfalls to Avoid
- Do not use long-term glucocorticoids (>1-2 years) as the adverse effects (osteoporosis, cataracts, cardiovascular disease) outweigh benefits 1, 4
- Do not underdose methotrexate—must reach 20-25 mg/week before concluding inadequate response 2, 5
- Do not switch within the same biologic class after first failure—change mechanism of action instead 2, 5